local_hospital

Alergo H2b s.r.o.

Address
Senny Trh 799/6, 945 01 Komarno, Slovakia

Chronic Spontaneous Urticaria Research

The team at Alergo H2b s.r.o. is conducting studies on Chronic Spontaneous Urticaria, a skin condition characterized by persistent hives, to evaluate a new BTK inhibitor for sustained symptom control.

  • Long‑term efficacy and safety
  • Relapse prevention strategies
  • Impact on patient quality of life

Results aim to support improved management options for patients in Komárno, Slovakia.

Atopic Dermatitis Clinical Studies

Investigations into moderate to severe atopic dermatitis are underway, focusing on the dose‑response relationship of emerging therapies to reduce eczema severity as measured by the EASI score.

  • Dose‑response characterization
  • EASI score improvement
  • Comprehensive safety assessment

The research contributes to expanding treatment options for skin and connective tissue diseases at the Komárno site.

Site Overview

assignment
2
connected trials
corporate_fare
1
sponsor
science
3
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
1
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 353 other sites in Slovakia

description
Trial volume
2
Outperforms 36% of sites
public
Therapeutic diversity
1areas
Outperforms 4% of sites
groups
Sponsor diversity
1sponsors
Outperforms 4% of sites

Therapeutic Area Benchmark — Slovakia

Select a therapeutic area to compare against other sites in Slovakia.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Slovakia

Market Share

Country: Slovakia

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Alergo H2b s.r.o.

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitisNovartis Pharma AGPhase IIRecruitingOct 2025

IMP list

lock Showing 1 of 3 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pimecrolimus1Unknown2025-10-282025-10-28

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.